Voriconazole: a new triazole antifungal agent.
Voriconazole is a second-generation azole antifungal agent that shows excellent in vitro activity against a wide variety of yeasts and molds. It can be given by either the intravenous or the oral route; the oral formulation has excellent bioavailability. The side effect profile of voriconazole is unique in that non-sight-threatening, transient visual disturbances occur in approximately 30% of patients given the drug. Rash (which can manifest as photosensitivity) and hepatitis also occur. The potential for drug-drug interactions is high and requires that careful attention be given to dosage regimens and monitoring of serum levels and effects of interacting drugs. Voriconazole has been approved for the treatment of invasive aspergillosis and refractory infections with Pseudallescheria/Scedosporium and Fusarium species, and it will likely become the drug of choice for treatment of serious infections with those filamentous fungi.
Johnson
Leonard B
LB
Division of Infectious Diseases, St. John Hospital & Medical Center, Wayne State University, Detroit, MI 48236, USA. Leonard.Johnson@stjohn.org
Kauffman
Carol A
CA
D000935:Antifungal Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy; D001230:Aspergillus / Q000187:drug effects; D002175:Candida / Q000187:drug effects*; D003872:Dermatitis / Q000209:etiology; D004347:Drug Interactions; D005076:Exanthema / Q000209:etiology; D006801:Humans; D008099:Liver / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D011743:Pyrimidines / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D014230:Triazoles / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole